Overview

Liposomal Bupivacaine in Total Knee Arthroplasty

Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Pain management after total knee arthroplasty is essential for optimized clinical outcomes and higher satisfaction. Exparel (Pacira Pharmaceuticals, Parsippany, New Jersey, USA) is a long-acting Bupivacaine extended release liposome compound that is injected peri-articularly or as regional block. The purpose of this study was to compare the analgesic efficacy of single administration of Exparel for local peri-articular infiltration versus adductor canal regional block.
Phase:
N/A
Details
Lead Sponsor:
Bronx-Lebanon Hospital Center Health Care System
Treatments:
Bupivacaine